上海 复星医药 （集团）股份有限公司（以下简称“复星医药”）于2025年6月24日发布公告，宣布修订《信息披露暂缓与豁免业务管理制度》，进一步规范公司信息披露行为，强化对涉及国家秘密、商业秘密等敏感信息的管控。修订后的制度明确，复星医药可依法对涉及国家秘密或可能违反保密规定的信息豁免披露，同时对符合特定情形的商业秘密（如核心技术、经营信息等）允许暂缓或豁免披露。制度要求，暂缓或豁免披露的信息需经...
Source Link上海 复星医药 （集团）股份有限公司（以下简称“复星医药”）于2025年6月24日发布公告，宣布修订《信息披露暂缓与豁免业务管理制度》，进一步规范公司信息披露行为，强化对涉及国家秘密、商业秘密等敏感信息的管控。修订后的制度明确，复星医药可依法对涉及国家秘密或可能违反保密规定的信息豁免披露，同时对符合特定情形的商业秘密（如核心技术、经营信息等）允许暂缓或豁免披露。制度要求，暂缓或豁免披露的信息需经...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.